https://www.selleckchem.com/pr....oducts/baf312-siponi
Recent progress in mouse model development should allow development of new treatments. Epigenetic changes are frequent in AITL and could be a promising target. Epigenetic changes are frequent in AITL and could be a promising target. Ovarian cancer (OC) is a heterogeneous disease and a mounting body of evidence shows that a 'one-size-fits-all' approach is obsolete. Differences in epidemiology, tumor biology, genetic profiles and treatment responses of these different types necessitate a tumor and patient-specific approach. Ninet
Like
Comment
Share
